Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cellular Immunotherapy for Septic Shock (CISS2) A Phase II Randomized Controlled Trial

NCT03369275 is registered in ClinicalTrials.gov with Ottawa Hospital Research Institute as lead sponsor.

NCT NCT03369275
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03369275 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cellular Immunotherapy for Septic Shock (CISS2) A Phase II Randomized Controlled Trial
Lead sponsor
Ottawa Hospital Research Institute
Phase
Phase 2
Overall status
Unknown status
Start date
March 31, 2018
Completion date
October 31, 2020
Enrollment
114 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

infection, inflammation, pathologic processes, sepsis, septic shock, shock, systemic inflammatory response syndrome